Pro 2013-001 (Announcement on Resolution of 8th Board of Directors of Jianfeng Group)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2013-001
Zhejiang Jianfeng Group Co., Ltd.
Resolution Announcement of the 8th Meeting of the 8th Board of Directors
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
On December 20, 2012, Zhejiang Jianfeng Group Co., Ltd. issued a notice to convene the eighth meeting of the eighth board of directors by fax, e-mail, telephone, and personal delivery. On December 31, 2012, the meeting was held as scheduled by means of communication. The company currently has nine directors, and nine directors participating in the voting , comply with the provisions of the "Company Law" and the "Articles of Association", and the resolutions made are legal and valid. The meeting passed the following resolutions:
1. the "Proposal on the Company's Compliance with the Conditions for Issuing Corporate Bonds"
According to the "the People's Republic of China Company Law", "the People's Republic of China Securities Law", "Corporate Bond Issuance Pilot Measures" And other relevant regulations, in accordance with the conditions for listed companies to issue corporate bonds, the company meets the conditions and requirements stipulated by the current policies and laws and regulations for issuing corporate bonds, eligible to issue corporate bonds.
Voting result :__9__ votes yes, __0__ votes no, __0__ votes abstaining.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation and voting.
2. "Proposal on Issuing Corporate Bonds";
Meeting deliberated and approved item by item: 1 , issuance scale ; 2 , allotment arrangement to the original shareholders of the company ; 3 , bond term ; 4 , bond interest rate and determination method ; 5 , issuance method ; 6 , issuance object ; 7 , guarantee arrangement; 8 , use of raised funds ; 9 , listing of issued bonds ; 10 , Effective date of resolution . For details, please refer to the "Announcement on the Issuance of Corporate Bonds" published on the same day. At the meeting of
, there were 82 votes , results were all :__9__ votes in favor, __0__ votes against, and __0__ votes abstained.
The above proposals still need to be submitted to the general meeting of shareholders for deliberation and submitted to the China Securities Regulatory Commission for approval.3. "Proposal on requesting the company's general meeting of shareholders to authorize the board of directors
and its authorized person to handle matters related to the issuance of corporate bonds"
According to the company's current corporate bond issuance and listing Arrangements, in order to complete the relevant work of this corporate bond legally, efficiently and orderly, in accordance with the "the People's Republic of China Company Law", "the People's Republic of China Securities Law", "Corporate Bond Issuance Pilot Measures" and other laws and regulations and the relevant provisions of the "Articles of Association of Zhejiang Jianfeng Group Co., Ltd.", the company's board of directors intends to request the company's general meeting of shareholders to authorize the board of directors to handle All matters related to the issuance of corporate bonds, the specific content includes but is not limited to:
1, within the scope permitted by laws and regulations, according to the specific conditions of the company and the market, formulate the specific issuance plan of this issue of corporate bonds and revise and adjust the issuance terms of this issue of corporate bonds, including but not limited to the specific issuance scale, bond term, bond interest rate and determination method, issuance timing, whether to issue in installments and the number of issues and the issuance scale of each issue, online and offline issuance ratio, whether to design the resale clause and redemption clause, whether to provide guarantee and guarantee method, the time limit and method of repayment of principal and interest, whether to allocate to shareholders and the specific arrangement of placing to shareholders, listing place and decision to raise funds the specific use of all matters relating to the issuance of the Company's bonds;
2, decide and hire intermediaries to participate in this corporate bond issuance;
3, select bond trustee, sign "bond trustee management agreement" and formulate "bondholder meeting rules";
4, handle the declaration of this corporate bond issuance, and after the completion of this issuance, to handle the listing of the bonds issued, including but not limited to formulation, approval, authorization, signing, execution, modification and completion of all necessary documents related to the issuance and listing of corporate bonds, contract / agreement, contract ( includes but not limited to prospectus, sponsorship agreement, underwriting agreement, bond trusteeship agreement, listing agreement, various announcements and other legal documents ) and appropriate information disclosure in accordance with laws, regulations and other regulatory documents;
5, request the general meeting of shareholders to authorize the board of directors to decide the amount of funds raised to repay company debt and supplement working capital according to the company's financial situation.
6. If the regulatory authority's policy on the issuance of corporate bonds changes or market conditions change, except for matters involving relevant laws, regulations and the company's articles of association that must be re-voted by the general meeting of shareholders, Authorize the board of directors to make corresponding adjustments to the specific corporate bond issuance plan and other related matters based on the new policies and opinions of the regulatory authority or new market conditions;
7. When the market environment or policies and regulations undergo major changes, the board of directors is authorized to decide whether to continue the corporate bond issuance based on the actual situation.
8, handle all other necessary matters related to the issuance of corporate bonds and listing.
. This authorization shall be from the date of deliberation and approval by the general meeting of shareholders to the date of completion of the above authorization.
The board of directors of the company intends to authorize the chairman and the secretary of the board of directors to handle specific matters related to this issuance in accordance with the scope of authorization of the general meeting of shareholders.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
This proposal still needs to be reviewed and approved by the company's shareholders' meeting.
4. "Proposal on Requiring the General Meeting of Shareholders of the Company to Authorize the Board of Directors to Take Repayment Safeguard Measures in Case of Expected Failure to Pay Bond Principal and Interest on Time or Failure to Pay Bond Principal and Interest on Time"
The Company Requested the General Meeting of Shareholders to Authorize the Board of Directors to Make the following Resolutions and Take Corresponding Measures :
1 , no distribution of profits to shareholders;
2 , suspending the implementation of capital expenditure projects such as major foreign investment, mergers and acquisitions;
3 , reduce or suspend the salaries and bonuses of directors and senior management personnel;
4 , the main responsible person shall not be transferred.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
This proposal still needs to be reviewed and approved by the company's shareholders' meeting.
Proposal of 5. on Convening the First Extraordinary General Meeting of Shareholders in 2013
Decided to Convene the First Extraordinary General Meeting of Shareholders in 2013 on 1 March 22 (Tuesday) in 2013 , for details, please refer to the "Notice on Convening the First Extraordinary General Meeting of Shareholders in 2013 " published on the same day.
voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
December 31, 2012
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31